高级检索
当前位置: 首页 > 详情页

Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China(Open Access)

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Breast Center Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [2]BreastCenter Department, Henan Cancer Hospital, Zhengzhou, China [3]Breast Center Department, Affiliated Hospitalof Qingdao University, Qingdao, China [4]Breast Center Department, The First Affiliated Hospital of ZhejiangUniversity, Hangzhou, China [5]Department of Oncology, Jiangsu Province Hospital, Nanjing, China [6]Departmentof Breast Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China [7]Department ofBreast Cancer, The Fifth Medical Center of the General Hospital of the Chinese People’s Liberation Army, Beijing,China [8]Department of General Surgery, The First Hospital of Peking University, Beijing, China [9]Departmentof Breast Surgery, The First Hospital of Jilin University, Jilin, China [10]Department of Breast and Thyroid, DalianCentral Hospital, Dalian, China
出处:
ISSN:

摘要:
Stage IV breast cancer is metastatic breast cancer (MBC). Because real-world data are lacking in China, our research attempts to explore the effect of locoregional surgery on the prognosis of patients with MBC. A total of 987 patients from 10 hospitals and 2 databases in East China (2004–2018) were included in this study. Overall, 47% of patients underwent locoregional surgery, and 53% did not. Surgeons tended to perform surgery on patients with small tumours (T1/T2), positive hormone receptor (HR) markers, and metastatic sites confined to a single organ and non-visceral sites (bone only/others) (each p < 0.05). Kaplan–Meier survival curves and the log-rank test showed that median survival was longer for patients who had locoregional surgery than for those who did not (45.00 vs. 28.00 months; p < 0.001). Patients who underwent surgery after systemic treatment had better survival than those who underwent surgery immediately (p < 0.001). In most subgroups, overall survival (OS) was significantly longer in the surgery group than in the no-surgery group (each p < 0.05), except for brain metastases and triple negative breast cancer. Therefore, we concluded that locoregional surgery for the primary tumour in MBC patients was associated with a marked reduction in risk of dying except for patients with brain metastases or triple-negative subtype. © 2020, The Author(s).

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2020]版:
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
最新[2025]版:
大类 | 3 区 综合性期刊
小类 | 3 区 综合性期刊
JCR分区:
出版当年[2020]版:
Q1 MULTIDISCIPLINARY SCIENCES
最新[2023]版:
Q1 MULTIDISCIPLINARY SCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Breast Center Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
通讯作者:
通讯机构: [1]Breast Center Department, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [7]Department ofBreast Cancer, The Fifth Medical Center of the General Hospital of the Chinese People’s Liberation Army, Beijing,China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号